BACK-UP YOUR LIFE!

Store your own stem cells today for tomorrow! With your decision you will be amongst those who are already open to all future medical options.

TICEBA - Advantages at a glance - Picture 01TICEBA - Advantages at a glance - Picture 02


Our Exclusive Service Contains

  • Removal and storage of the cells from the skin and the stem cells contained therein
  • Preparation
  • Cryogenic storage and conservation of the skin tissue with the stem cells contained therein

Process of Sampling and Conservation

In a short ambulant surgery the required piece of skin with a size of about 5 cm² (2 in²) is obtained from a cosmetically inconspicuous place, e.g. from behind the ear.

The subsequent preparation of the tissue occurs for the purpose of preparation of the cryoconservation of the cells in liquid nitrogen.

Freezing of the cells is carried out in accordance with the latest technical and scientific standard in our cryostorage tanks at up to -196 degrees Celsius (-320.8 degrees Fahrenheit) where the treated skin tissue is safely stored.

TICEBA - Process of Sampling and Conservation


Application of Stem Cells

In the case of medical need, we retrieve your stem cells as well as your tissue. If this case occurs, just get in touch with us. We assure that your tissue with the stem cells contained therein is available at the right place at the right time.

News
Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter